Abstract
The primate-exclusive MRGPRX2 G protein-coupled receptor (GPCR) has been suggested to modulate pain and itch. Despite putative peptide and small-molecule MRGPRX2 agonists, selective nanomolar-potency probes have not yet been reported. To identify a MRGPRX2 probe, we first screened 5,695 small molecules and found that many opioid compounds activated MRGPRX2, including (−)- and (+)-morphine, hydrocodone, sinomenine, dextromethorphan, and the prodynorphin-derived peptides dynorphin A, dynorphin B, and α- and β-neoendorphin. We used these to select for mutagenesis-validated homology models and docked almost 4 million small molecules. From this docking, we predicted ZINC-3573—a potent MRGPRX2-selective agonist, showing little activity against 315 other GPCRs and 97 representative kinases—along with an essentially inactive enantiomer. ZINC-3573 activates endogenous MRGPRX2 in a human mast cell line, inducing degranulation and calcium release. MRGPRX2 is a unique atypical opioid-like receptor important for modulating mast cell degranulation, which can now be specifically modulated with ZINC-3573.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Allen, J.A. & Roth, B.L. Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 51, 117–144 (2011).
Overington, J.P., Al-Lazikani, B. & Hopkins, A.L. How many drug targets are there? Nat. Rev. Drug Discov. 5, 993–996 (2006).
Huang, X.P. et al. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 527, 477–483 (2015).
Rask-Andersen, M., Masuram, S. & Schiöth, H.B. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. Annu. Rev. Pharmacol. Toxicol. 54, 9–26 (2014).
Fredriksson, R. & Schiöth, H.B. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol. Pharmacol. 67, 1414–1425 (2005).
Kroeze, W.K. et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat. Struct. Mol. Biol. 22, 362–369 (2015).
Ngo, T. et al. Identifying ligands at orphan GPCRs: current status using structure-based approaches. Br. J. Pharmacol. 173, 2934–2951 (2016).
Isberg, V. et al. Computer-aided discovery of aromatic l-α-amino acids as agonists of the orphan G protein-coupled receptor GPR139. J. Chem. Inf. Model. 54, 1553–1557 (2014).
Mason, J.S., Bortolato, A., Congreve, M. & Marshall, F.H. New insights from structural biology into the druggability of G-protein-coupled receptors. Trends Pharmacol. Sci. 33, 249–260 (2012).
Zylka, M.J., Dong, X., Southwell, A.L. & Anderson, D.J. Atypical expansion in mice of the sensory neuron-specific Mrg G-protein-coupled receptor family. Proc. Natl. Acad. Sci. USA 100, 10043–10048 (2003).
Dong, X., Han, S., Zylka, M.J., Simon, M.I. & Anderson, D.J. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 106, 619–632 (2001).
Lembo, P.M. et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nat. Neurosci. 5, 201–209 (2002).
Tatemoto, K. et al. Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem. Biophys. Res. Commun. 349, 1322–1328 (2006).
Kamohara, M. et al. Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides. Biochem. Biophys. Res. Commun. 330, 1146–1152 (2005).
Subramanian, H. et al. β-Defensins activate human mast cells via Mas-related gene X2. J. Immunol. 191, 345–352 (2013).
Robas, N., Mead, E. & Fidock, M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J. Biol. Chem. 278, 44400–44404 (2003).
Malik, L. et al. Discovery of non-peptidergic MrgX1 and MrgX2 receptor agonists and exploration of an initial SAR using solid-phase synthesis. Bioorg. Med. Chem. Lett. 19, 1729–1732 (2009).
Johnson, T. & Siegel, D. Complanadine A, a selective agonist for the Mas-related G protein-coupled receptor X2. Bioorg. Med. Chem. Lett. 24, 3512–3515 (2014).
McNeil, B.D. et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519, 237–241 (2015).
Southern, C. et al. Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J. Biomol. Screen. 18, 599–609 (2013).
Sromek, A.W. et al. Preliminary pharmacological evaluation of enantiomeric morphinans. ACS Chem. Neurosci. 5, 93–99 (2014).
Wang, M.H. et al. Activation of opioid mu-receptor by sinomenine in cell and mice. Neurosci. Lett. 443, 209–212 (2008).
Nagase, H. et al. The pharmacological profile of delta opioid receptor ligands, (+) and (−) TAN-67 on pain modulation. Life Sci. 68, 2227–2231 (2001).
White, K.L. et al. Identification of novel functionally selective κ-opioid receptor scaffolds. Mol. Pharmacol. 85, 83–90 (2014).
Horn, F. et al. GPCRDB: an information system for G-protein-coupled receptors. Nucleic Acids Res. 26, 275–279 (1998).
Lin, H., Sassano, M.F., Roth, B.L. & Shoichet, B.K. A pharmacological organization of G protein-coupled receptors. Nat. Methods 10, 140–146 (2013).
Irwin, J.J. & Shoichet, B.K. ZINC--a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45, 177–182 (2005).
Eswar, N. et al. Comparative protein structure modeling using MODELLER. Curr. Protoc. Protein Sci. 50, 2.9.1–2.9.31 (2007).
Yang, Q. & Sharp, K.A. Building alternate protein structures using the elastic network model. Proteins 74, 682–700 (2009).
Mysinger, M.M. & Shoichet, B.K. Rapid context-dependent ligand desolvation in molecular docking. J. Chem. Inf. Model. 50, 1561–1573 (2010).
Mysinger, M.M. et al. Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4. Proc. Natl. Acad. Sci. USA 109, 5517–5522 (2012).
Carlsson, J. et al. Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat. Chem. Biol. 7, 769–778 (2011).
Jacobson, M.P., Friesner, R.A., Xiang, Z. & Honig, B. On the role of the crystal environment in determining protein side chain conformations. J. Mol. Biol. 320, 597–608 (2002).
Ballesteros, J.A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure–function relations in G-protein-coupled receptors. Methods Neurosci. 25, 366–428 (1995).
O'Connor, C. et al. NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor. Proc. Natl. Acad. Sci. USA 112, 11852–11857 (2015).
Irwin, J.J. & Shoichet, B.K. Docking screens for novel ligands conferring new biology. J. Med. Chem. 59, 4103–4120 (2016).
Jacquet, Y.F., Klee, W.A., Rice, K.C., Iijima, I. & Minamikawa, J. Stereospecific and nonstereospecific effects of (+)- and (−)-morphine: evidence for a new class of receptors? Science 198, 842–845 (1977).
Baldo, B.A. & Pham, N.H. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesth. Intensive Care 40, 216–235 (2012).
Rosow, C.E., Moss, J., Philbin, D.M. & Savarese, J.J. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 56, 93–96 (1982).
Kumar, K. & Singh, S.I. Neuraxial opioid-induced pruritus: an update. J. Anaesthesiol. Clin. Pharmacol. 29, 303–307 (2013).
Hutchinson, M.R. et al. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol. Rev. 63, 772–810 (2011).
Yamasaki, H. Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum. Acta Med. Okayama 30, 1–20 (1976).
Zajac, M. et al. [Recreational usage of dextromethorphan—analysis based on internet users experiences]. Przegl. Lek. 70, 525–527 (2013).
Scimemi, A. & Beato, M. Determining the neurotransmitter concentration profile at active synapses. Mol. Neurobiol. 40, 289–306 (2009).
Podvin, S., Yaksh, T. & Hook, V. The emerging role of spinal dynorphin in chronic pain: a therapeutic perspective. Annu. Rev. Pharmacol. Toxicol. 56, 511–533 (2016).
Sweetnam, P.M., Neale, J.H., Barker, J.L. & Goldstein, A. Localization of immunoreactive dynorphin in neurons cultured from spinal cord and dorsal root ganglia. Proc. Natl. Acad. Sci. USA 79, 6742–6746 (1982).
Rojewska, E., Makuch, W., Przewlocka, B. & Mika, J. Minocycline prevents dynorphin-induced neurotoxicity during neuropathic pain in rats. Neuropharmacology 86, 301–310 (2014).
Bienenstock, J. et al. Mast cell/nerve interactions in vitro and in vivo. Am. Rev. Respir. Dis. 143, S55–S58 (1991).
Barelier, S., Sterling, T., O'Meara, M.J. & Shoichet, B.K. The recognition of identical ligands by unrelated proteins. ACS Chem. Biol. 10, 2772–2784 (2015).
Akuzawa, N., Obinata, H., Izumi, T. & Takeda, S. Morphine is an exogenous ligand for MrgX2, a G-protein-coupled receptor for cortistatin. J. Cell Animal Biol. 2, 004–009 (2007).
Wu, H.E., Schwasinger, E.T., Terashvili, M. & Tseng, L.F. dextro-Morphine attenuates the morphine-produced conditioned place preference via the sigma(1) receptor activation in the rat. Eur. J. Pharmacol. 562, 221–226 (2007).
Kirshenbaum, A.S. et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk. Res. 27, 677–682 (2003).
Jordan, M., Schallhorn, A. & Wurm, F.M. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 24, 596–601 (1996).
Staats, H.F. et al. A mast cell degranulation screening assay for the identification of novel mast cell activating agents. MedChemComm 4, 88–94 (2013).
Pei, J., Kim, B.H. & Grishin, N.V. PROMALS3D: a tool for multiple protein sequence and structure alignments. Nucleic Acids Res. 36, 2295–2300 (2008).
Jacobson, M.P. Epilepsy in aging populations. Curr. Treat. Options Neurol. 4, 19–30 (2002).
Sharp, K.A. Polyelectrolyte electrostatics: salt dependence, entropic, and enthalpic contributions to free energy in the nonlinear Poisson–Boltzmann model. Biopolymers 36, 227–243 (1995).
Meng, E.C., Shoichet, B.K. & Kuntz, I.D. Automated docking with grid-based energy evaluation. J. Comput. Chem. 13, 505–524 (1992).
Li, J., Zhu, T., Cramer, C.J. & Truhlar, D.G. New class IV charge model for extracting accurate partial charges from wave functions. J. Phys. Chem. A 102, 1820–1831 (1998).
Chambers, C.C., Hawkins, G.D., Cramer, C.J. & Truhlar, D.G. Model for aqueous solvation based on class IV atomic charges and first solvation shell effects. J. Phys. Chem. 100, 16385–16398 (1996).
Paruch, K. et al. Discovery of Dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med. Chem. Lett. 1, 204–208 (2010).
Acknowledgements
Support was given by National Institutes of Health (NIH) grants U01104974 (B.L.R., B.K.S. and W.K.K.), the NIH Department of Pharmacology Training Grant (K.L.), a Genentech Foundation Pre-doctoral Fellowship (J.K.), and a PhRMA Foundation Predoctoral Fellowship (K.L.). We thank the National Institute on Drug Abuse Drug Supply Program for supplying the morphine and codeine analogs and the glucuronidated or acetylated metabolites used in this study.
Author information
Authors and Affiliations
Contributions
K.L. performed the in vitro pharmacology and molecular biology and wrote the paper. J.K. designed and developed homology models, carried out docking screens, analyzed results, and wrote the paper. J.L. synthesized the probe enantiomers. X.-P.H. performed GPCRome screening and assisted with in vitro pharmacology experiments. J.D.M. performed binding studies and in vitro pharmacology. W.K.K. assisted in the in vitro small-molecule screening and helped with data and statistical analyses. T.C. performed in vitro pharmacology experiments. H.N. synthesized (+)-TAN-67 and KNT-127. F.I.C. synthesized several compounds and advised structure–activity relationship studies. J.J. supervised chemical synthesis of probe enantiomers. B.L.R. and B.K.S. coordinated and supervised the project, and with the other authors wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Results, Supplementary Tables 1–3 and Supplementary Figures 1–12 (PDF 3279 kb)
Supplementary Note
Chemical compound characterization for selective probes (R)-ZINC-3573 and (S)-ZINC-3573 (PDF 348 kb)
Supplementary Data Set 1
PDB file for viewing ZINC-9232 docked in the MRGPRX2 model structure (TXT 207 kb)
Supplementary Data Set 2
PDB file for viewing dextromethorphan docked in the MRGPRX2 model structure (TXT 207 kb)
Rights and permissions
About this article
Cite this article
Lansu, K., Karpiak, J., Liu, J. et al. In silico design of novel probes for the atypical opioid receptor MRGPRX2. Nat Chem Biol 13, 529–536 (2017). https://doi.org/10.1038/nchembio.2334
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.2334
This article is cited by
-
Copper-catalyzed synthesis of pyrazolo[1,5-a]pyrimidine based triazole-linked glycohybrids: mechanistic insights and bio-applications
Scientific Reports (2024)
-
Proinflammatory chemokine CXCL14 activates MAS-related G protein-coupled receptor MRGPRX2 and its putative mouse ortholog MRGPRB2
Communications Biology (2024)
-
Allergic and other adverse reactions to drugs used in anesthesia and surgery
Anesthesiology and Perioperative Science (2023)
-
Opioid toxicity: histamine, hypersensitivity, and MRGPRX2
Archives of Toxicology (2023)
-
Determination of key residues in MRGPRX2 to enhance pseudo-allergic reactions induced by fluoroquinolones
Scientific Reports (2022)